1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > B-Cell Lymphomas-Pipeline Insights, 2017

B-Cell Lymphomas-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ B-Cell Lymphomas-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Lymphomas. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for B-Cell Lymphomas. DelveInsight’s Report also assesses the B-Cell Lymphomas therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of B-Cell Lymphomas
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the B-Cell Lymphomas pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for B-Cell Lymphomas and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

B-Cell Lymphomas-Pipeline Insights, 2017
Illustrative

- B-Cell Lymphomas Overview
- B-Cell Lymphomas Pipeline Therapeutics
- B-Cell Lymphomas Therapeutics under Development by Companies
- B-Cell Lymphomas Filed and Phase III Products
- Comparative Analysis
- B-Cell Lymphomas Phase II Products
- Comparative Analysis
- B-Cell Lymphomas Phase I and IND Filed Products
- Comparative Analysis
- B-Cell Lymphomas Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- B-Cell Lymphomas - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- B-Cell Lymphomas - Discontinued Products
- B-Cell Lymphomas - Dormant Products
- Companies Involved in Therapeutics Development for B-Cell Lymphomas
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for B-Cell Lymphomas, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- B-Cell Lymphomas Assessment by Monotherapy Products
- B-Cell Lymphomas Assessment by Combination Products
- B-Cell Lymphomas Assessment by Route of Administration
- B-Cell Lymphomas Assessment by Stage and Route of Administration
- B-Cell Lymphomas Assessment by Molecule Type
- B-Cell Lymphomas Assessment by Stage and Molecule Type
- B-Cell Lymphomas Therapeutics - Discontinued Products
- B-Cell Lymphomas Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for B-Cell Lymphomas, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- B-Cell Lymphomas Assessment by Monotherapy Products
- B-Cell Lymphomas Assessment by Combination Products
- B-Cell Lymphomas Assessment by Route of Administration
- B-Cell Lymphomas Assessment by Stage and Route of Administration
- B-Cell Lymphomas Assessment by Molecule Type
- B-Cell Lymphomas Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global non-Hodgkin’s lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach ...

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global T-cell lymphoma market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Denmark

  • January 2017
    8 pages
  • Lymphoma  

  • Denmark  

View report >

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Cancer Statistics and Autoimmune Disease Statistics in the US

  • January 2017
    152 pages
  • Cancer  

    Autoimmune Dise...  

    Dermatological ...  

  • United States  

View report >

Related Market Segments :

Lymphoma

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.